This report examines the savings generated by increasing access to a new medication category—proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)—which effectively manages dyslipidemia (high cholesterol) in two populations at high risk for cardiovascular disease.
Reducing Cardiovascular Disease in Canada: The Impact of PCSK9 Inhibitors in High-Risk Populations
Reducing Cardiovascular Disease in Canada: The Impact of PCSK9 Inhibitors in High-Risk Populations
Health and Healthcare
$0.00
Cardiovascular disease (CVD) prevalence incurs significant costs to governments and society in the form of hospitalizations, disease management, and lost productivity. Also, some individuals are at increased risk of a first or repeat CVD event due to high LDL cholesterol (LDL-C) levels. This report investigates the impact of increasing access to a new medication category—proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i)—which effectively manages dyslipidemia (high cholesterol) in two high-risk populations.
Discover why PCSK9i, recommended by Canadian guidelines for the treatment of dyslipidemia in high-risk patients, can lead to billions of dollars in direct cost savings to the Canadian health care system and indirect cost savings from lost productivity due to premature mortality and hospitalizations.
Customers Who Downloaded This Also Liked
Require an accessible version of this research?
Upon request, The Conference Board of Canada offers accessible versions of research. Please contact us to request your accessible version.
Learn more about our accessibility policies.
